Thyroidectomy - UpToDate

2/12/24, 6:37 PM Thyroidectomy - UpToDate
Official reprint from UpToDate®

www.uptodate.com © 2024 UpToDate, Inc. and/or its affiliates. All Rights Reserved.
Thyroidectomy
AUTHORS: Tracy S Wang, MD, MPH, Melanie L Lyden, MD, MHPE, Julie Ann Sosa, MD, MA, FACS
SECTION EDITOR: Sally E Carty, MD, FACS
DEPUTY EDITOR: Wenliang Chen, MD, PhD
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Jan 2024.

This topic last updated: Aug 11, 2023.
INTRODUCTION
Over the last century, thyroid surgery has evolved from a dangerous and bloody undertaking to a safe operation with favorable
outcomes but few major risks, especially when performed by experienced surgeons [1-6].
Thyroid surgery is performed for a number of benign and malignant conditions, which are discussed in detail elsewhere (see
'Indications' below). In this topic, we discuss various surgical aspects of thyroidectomy, including preoperative evaluation and
preparation, operative management, postoperative care, and complications.
INDICATIONS
Thyroidectomy may be performed for a number of benign and malignant conditions, including:
● Thyroid nodules. (See "Diagnostic approach to and treatment of thyroid nodules".)
● Hyperthyroidism. (See "Surgical management of hyperthyroidism", section on 'Role of surgery'.)
https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 1/65

● Obstructive or substernal goiter. (See "Treatment of benign obstructive or substernal goiter", section on 'Approach to
surgery'.)
● Differentiated (papillary or follicular) thyroid cancer. (See "Differentiated thyroid cancer: Surgical treatment".)
● Medullary thyroid cancer. (See "Medullary thyroid cancer: Surgical treatment and prognosis".)
● Anaplastic thyroid cancer. (See "Anaplastic thyroid cancer", section on 'Our approach to treatment'.)
● Primary thyroid lymphoma – Primary thyroid lymphoma is treated with chemotherapy and/or radiation. The role of
surgery is limited to obtaining tissue biopsy.
● Metastases to the thyroid – Metastases to the thyroid gland from extrathyroidal primary cancers are rare and are most
commonly from renal cell carcinoma in clinical series and the lung in autopsy series [7-9]. Local control can be achieved
with thyroid surgery in patients with isolated metastasis to the thyroid.
PREOPERATIVE EVALUATION AND PREPARATION
With few exceptions, thyroidectomy is elective surgery. Thus, any major medical issues should be addressed before proceeding
to the operating room [10]. (See "Evaluation of cardiac risk prior to noncardiac surgery" and "Evaluation of perioperative
pulmonary risk".)
All patients undergoing thyroid surgery require preoperative imaging, laboratory testing, and laryngeal examination as
discussed below. Patients with hyperparathyroidism and those undergoing reoperations need additional preparation [6].
Thyroid imaging — Diagnostic thyroid ultrasound is performed in all patients with a suspected thyroid nodule, nodular goiter,
or thyroid abnormality detected by another imaging modality. In patients undergoing thyroid surgery for malignant conditions,
ultrasound examination of the contralateral thyroid lobe as well as the lateral and central compartment cervical lymph nodes
should also be performed [6,11]. (See "Overview of the clinical utility of ultrasonography in thyroid disease" and "Diagnostic
approach to and treatment of thyroid nodules", section on 'Thyroid ultrasonography'.)

Additional imaging modalities, such as computed tomography (CT), positron emission tomography (PET), or magnetic
resonance imaging (MRI), may be offered to patients who are suspected of harboring advanced diseases (eg, invasive primary
tumor or multiple/bulky lymph node involvement) [12]. CT and MRI can detect extrathyroidal tumor extension into adjacent
structures as well as substernal or retropharyngeal diseases [13]. (See "Differentiated thyroid cancer: Surgical treatment",
section on 'Importance of preoperative imaging'.)
Laboratory testing — For all patients undergoing thyroid surgery, a serum thyroid-stimulating hormone (TSH) level can
determine whether the patient is euthyroid, hyperthyroid, or hypothyroid. A serum calcium level can help identify patients who
have concomitant parathyroid disorders [6]. (See "Laboratory assessment of thyroid function" and "Primary
hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation".)
For patients diagnosed with medullary thyroid cancer or highly suspected to have medullary thyroid cancer based on family
history, preoperative evaluation should also include measurement of serum calcitonin, carcinoembryonic antigen (CEA), genetic
testing for germline RET mutations, and biochemical evaluation for coexisting endocrinopathies, such as hyperparathyroidism
or pheochromocytoma [14-16]. Medullary thyroid cancer may be hereditary, as in multiple endocrine neoplasia type 2 (MEN2A
or MEN2B) syndrome. The evaluation of patients with medullary thyroid cancer is discussed in detail elsewhere. (See "Medullary
thyroid cancer: Clinical manifestations, diagnosis, and staging", section on 'Evaluation'.)
Molecular testing may be performed on the biopsy specimen. This may guide the extent of thyroidectomy. (See "Evaluation and
management of thyroid nodules with indeterminate cytology in adults".)
Laryngeal examination — Injury or trauma to the recurrent laryngeal nerve (RLN) during thyroid surgery can result in vocal
cord paralysis. Thus, occult RLN paresis and/or vocal cord paralysis diagnosed before the surgery can facilitate operative
planning and patient counseling. In preoperative discussion, the surgeon should disclose to the patient the possibility,
likelihood, and implications of permanent laryngeal dysfunction [6].
Preoperative assessment of the vocal cord function can be done by listening to the patient's voice, direct or indirect
laryngoscopy, videostroboscopy (which provides a magnified, slow-motion view of the vocal cords), or laryngeal ultrasound [17].
(See "Inducible laryngeal obstruction (paradoxical vocal fold motion)", section on 'Laryngoscopy'.)

Although some surgeons advocate routine laryngoscopy in all patients undergoing thyroidectomy because voice change was
only observed in one-third of patients with a vocal cord paralysis [18], routine testing has not been shown to be either
obligatory or cost effective [12,19]. Published clinical guidelines recommend performing preoperative laryngeal examination
selectively in patients determined to be at high risk, including [6,12,20]:
● Patients with preoperative hoarseness or voice changes

● Patients with history of prior neck or mediastinal surgery, both thyroid and nonthyroid
● Patients with extrathyroidal extension of tumor posteriorly
● Patients with bulky lymphadenopathy in the central compartment or jugular chain
Additionally, invasive thyroid cancer is associated with a higher risk of occult RLN paresis/vocal cord paralysis. In one study of
365 patients, preoperative vocal cord paralysis was diagnosed by laryngoscopy in 70 percent of patients with invasive disease
but only 0.3 percent of patients with noninvasive disease [21].
Preoperative management of hyperthyroidism — According to several clinical guidelines that cover the diagnosis and
management of hyperthyroidism and other causes of thyrotoxicosis, patients undergoing surgery for hyperthyroidism should
receive [6,22]:
● Preoperative antithyroid medications and/or beta blockade to avoid thyroid storm.
● Preoperative oral Lugol's solution (potassium iodide, SSKI) to block iodine uptake and the secretion of thyroid hormone
[23]. Lugol's solution may also decrease vascularity of the thyroid gland and reduce intraoperative bleeding.
● Preoperative vitamin D and calcium supplementation to reduce the risk of symptomatic hypocalcemia postoperatively [24].
Patients with previous gastric bypass surgery are at an increased risk for developing recalcitrant, symptomatic
hypocalcemia after thyroidectomy, the management of which may be difficult [25].
Medical optimization of patients undergoing surgery for hyperthyroidism is further discussed in another topic. (See "Surgical
management of hyperthyroidism", section on 'Preoperative preparation'.)

Reoperative thyroid surgery — Reoperative thyroidectomy refers to thyroid surgery performed in patients who have had one
or more previous thyroid surgeries or other neck operations such as cervical spine surgery via an anterior approach,
parathyroidectomy, tracheostomy, or carotid endarterectomy. Reoperative thyroid surgery is technically challenging due to the
presence of adhesions and scar tissues in the operative field, has different indications and strategies, and can be associated
with higher rates of complications such as RLN injury and hypoparathyroidism [6,20,26,27].
The risks and benefits should be carefully weighed before reoperative thyroid surgery, especially when options for nonoperative
management exist (eg, for benign indications) [20,26,27]. Once the decision is made to operate, the surgeon must carefully
review all operative and pathology reports from previous operations to determine the prior extent of disease and the visibility,
location, and possible loss of parathyroid glands during the previous operations. In many cases, formal review of pathology
slides from the previous surgeries may also be informative.
The timing of performing a completion thyroidectomy after a partial thyroidectomy that reveals thyroid cancer remains
controversial but has not been shown to impact complication rates [28]. Many surgeons perform completion thyroidectomy
either within five to seven days after the initial thyroid lobectomy before intense inflammation in the operative field has set in or
delay the operation for at least six weeks to allow time for the inflammation to subside.
OPERATIVE MANAGEMENT
Surgical prophylaxis
Antibiotics — Thyroid surgery has a very low infection rate because it is a clean procedure performed in a well-vascularized
area, and thus antibiotic prophylaxis is generally not required [6,29,30]. In patients at high risk for infection, such as those with
immunocompromise or poorly controlled diabetes, preoperative antibiotics such as cefazolin can be administered [31,32]. To be
effective, preoperative prophylactic antibiotics should be administered within one hour of incision [33-35]. (See "Antimicrobial
prophylaxis for prevention of surgical site infection in adults".)
Antiemetics — Prophylactic antiemetics should be given because postoperative nausea and vomiting occur frequently after
thyroidectomy. In one trial, a single 8 mg dose of dexamethasone given preoperatively significantly decreased postoperative

nausea and vomiting in patients undergoing thyroidectomy [36]. The prevention and treatment of postoperative nausea and
vomiting are reviewed in another topic. (See "Overview of post-anesthetic care for adult patients", section on 'Postoperative
nausea and vomiting' and "Postoperative nausea and vomiting".)
Venous thromboembolism prophylaxis — For patients undergoing thyroid surgery under general anesthesia, mechanical
methods of thromboprophylaxis, such as sequential compression devices, should be employed. After surgery, patients are
encouraged to get out of bed and ambulate as early as possible; most patients are able to do so in the evening after their
surgery. (See "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients".)
Anesthesia — Thyroid surgery can be performed under general or local/regional anesthesia. While the vast majority of
thyroidectomies are performed under general endotracheal anesthesia, local or regional anesthesia can be used selectively
provided that the anatomy and pathology are favorable, the patient is able to communicate with the operating room staff and
does not mind being conscious, and clinician expertise in performing a cervical plexus block is available ( figure 1). (See
"Anesthesia for patients with thyroid disease and for patients who undergo thyroid or parathyroid surgery", section on 'Choice
of anesthetic technique'.)
Patient position and skin preparation — The patient is placed on the operating table in a supine, semi-Fowler, or "beach-
chair" position, typically with the neck in extension. A roll can be placed transversely under the scapulae to facilitate exposure of
the anterior neck, and care should be taken to avoid neck hyperextension ( figure 2).
Although issues of operative access and safety also pertain, excessive neck extension during surgery can result in postoperative
pain. As an example, patients reported greater postoperative pain after undergoing thyroidectomy with than without neck
extension in a randomized trial [37]. Extensive hyperextension of the neck can also lead to vertigo, headache, and postoperative
nausea [38]. Patients with known cervical spine disease should be assessed preoperatively by an orthopedic surgeon or
neurosurgeon.
The skin of the anterior neck, from the lower lip/angle of the mandible to the anterior chest, should be prepared. If mediastinal
surgery is contemplated, the entire chest should be prepared and included in the operative field.

Incision — A Kocher (or collar) incision is made sharply on the anterior aspect of the midneck. Efforts should be made to place
this incision in an existing skin crease if possible. The incision length should be based on the size of the underlying thyroid
gland as well as patient body habitus [39]. A longer incision may be needed if the patient is obese, the gland is large, or the
neck is foreshortened, as with kyphoscoliosis ( figure 3).
Exposure — After the incision, dissection is carried down to the platysma muscle. A layer that is only a few millimeters thick, the
platysma muscle is divided along the course of the incision with cautery. Subplatysmal flaps are then elevated to above the level
of the thyroid cartilage superiorly, over the sternocleidomastoid muscles laterally, and the level of the sternal notch inferiorly
( figure 4).
The raphe between the strap muscles is opened in the midline avascular plane. Any enlarged lymph nodes in the midline
prelaryngeal area (Delphian nodes) should be excised because they can portend locally metastatic disease. The strap muscles,
which include the sternothyroid and sternohyoid muscles, are routinely preserved. However, if the thyroid tumor is adherent to
or frankly invades the strap muscles, any involved portion of the muscles should be resected en bloc with the tumor to maintain
a negative margin.
Dissection of the thyroid gland
● Starting with the isthmus, one lobe of the thyroid gland is dissected from medial to lateral across the anterior capsule.
● When the lateral border of that lobe is reached, the middle thyroid vein should be identified and divided. The thyroid lobe
is then rolled lateral to medial to display its posterior capsule and the tracheoesophageal groove, taking care not to enter
the thyroid capsule ( figure 5).
● The superior pole vessels are dissected out and ligated as close as possible to the thyroid capsule ( figure 6). All thyroid
tissues from the superior pole area are then removed. The external branch of the superior laryngeal nerve crosses the
vessels close to the superior pole of the thyroid. Retraction of the superior pole in a lateral and inferior direction during
dissection can facilitate visualization of the nerve.
● Dissection then continues down along the lateral aspect of the thyroid lobe. Mobilization of the superior pole may aid in
the identification of the recurrent laryngeal nerve (RLN). The RLN should be visually identified in the tracheoesophageal
groove and protected through its course. Placement of an oral or nasogastric tube, an esophageal stethoscope, or a
temperature probe facilitates identification of the tracheoesophageal groove and the RLN.
● The inferior vascular pedicle, along with any other blood vessels going to and from the thyroid in its vicinity, should be
ligated, which allows the thyroid lobe to be rolled up and onto the anterior surface of the trachea ( figure 7). A trial of
319 patients undergoing total thyroidectomy reported that dissection along the thyroid capsule with branch ligation of the
inferior thyroid arteries resulted in a lower rate of transient hypocalcemia compared with truncal ligation of the inferior
thyroid arteries (3.1 versus 22.9 percent) [40].
● The ligament of Berry should be divided as close to the trachea as possible near the insertion of the RLN or its branches
into the cricopharyngeus muscle ( figure 8). Great care has to be taken with this step because the ligament of Berry is
the most common site of injury for the RLN ( figure 9).
● The isthmus should then be separated from the anterior aspect of the trachea, and the pyramidal lobe followed as
cephalad as possible and resected en bloc with the thyroid ( figure 10).
● For a thyroid lobectomy and isthmusectomy, the dissection is then complete. A heavy clamp (eg, Kelly clamp) can be
applied across the junction of the isthmus and the contralateral thyroid lobe, the thyroid sharply divided, and the stump
oversewn with a hemostatic absorbable suture ( figure 11). Alternatively, a harmonic scalpel can be employed to divide
the isthmus. The specimen is then oriented and labeled for pathology.
● For a total thyroidectomy, dissection continues onto the contralateral lobe using gentle traction of the mobilized isthmus
to help expose that lobe. If any type of central neck dissection or cervical thymectomy is to be performed, it can be done
en bloc with the thyroidectomy specimen or separately after the thyroid lobe or gland has been removed.
Closure — Prior to closure, the surgical field is evaluated for hemostasis. The strap muscles are then reapproximated with
absorbable interrupted sutures at the midline ( figure 12). The platysma muscle is closed, followed by skin closure with
sutures or skin glue.
Extent of resection — The extent of initial thyroidectomy for certain thyroid diseases remains controversial. We suggest the
following approaches, which are consistent with published clinical guidelines [12]:
● Total thyroidectomy is the procedure of choice for patients with Graves' disease, medullary thyroid cancer, and for those
with a high-risk differentiated thyroid cancer. High-risk differentiated thyroid cancer is defined by tumor ≥4 cm or with
gross extrathyroidal extension, clinically apparent metastatic lymph nodes or distant metastases, or thyroid cancer in a
patient with prior radiation to the head and neck or family history of differentiated thyroid cancer in a first-degree relative
[41-43]. (See "Differentiated thyroid cancer: Overview of management" and "Medullary thyroid cancer: Surgical treatment
and prognosis" and "Surgical management of hyperthyroidism".)
● Either a total thyroidectomy or a thyroid lobectomy may be performed in patients with a low-risk differentiated thyroid
cancer, including those with a differentiated thyroid cancer between 1 and 4 cm without gross evidence of extrathyroidal
extension or clinical evidence of central or lateral compartment lymph node metastases [12]. (See "Differentiated thyroid
cancer: Surgical treatment".)
● Unifocal differentiated thyroid cancers that are <1 cm (papillary thyroid microcarcinoma) may undergo active surveillance
or thyroid lobectomy. Ideal patients for active surveillance include those with solitary tumors ≤1 cm with well-defined
margins and no evidence of lymph node metastases, who are older than 60 years, who understand that surgery may be
recommended in the future, and who are being managed by an experienced team [44,45]. When surgery is planned,
thyroid lobectomy is appropriate for most patients; in patients with a familial thyroid cancer and/or a history of radiation
to the face, neck, or chest, total thyroidectomy should be performed. (See "Differentiated thyroid cancer: Surgical
treatment" and "Diagnostic approach to and treatment of thyroid nodules", section on 'Malignant (Bethesda VI)'.)
In operative management, the minimum acceptable extent of thyroidectomy for unilateral diseases is a complete ipsilateral
lobectomy. Incomplete thyroid resections, such as thyroid "nodulectomy" or partial lobectomy, are no longer performed,
because they predispose patients to disease recurrence, scar tissue, and the need for reoperations.
Graves' disease or multinodular nontoxic goiter can best be treated with total thyroidectomy. Less extensive techniques, such as
unilateral lobectomy and isthmusectomy (Dunhill operation) or bilateral subtotal thyroidectomy, are not recommended,
because they either carry a greater risk of disease recurrence [41-43] or a greater risk of complications (eg, RLN injury or
hypoparathyroidism) if a reoperation is required [20,26,27]. (See "Surgical management of hyperthyroidism", section on 'Extent
of resection'.)

Lymphadenectomy — The extent of lymphadenectomy required at the time of thyroid surgery is based on the type of thyroid
malignancy and its risk of lymph node metastasis [11,12]. (See "Neck dissection for differentiated thyroid cancer".)
● All patients with a medullary, papillary, or follicular thyroid cancer and clinical or radiological evidence of
lymphadenopathy should undergo a therapeutic lymphadenectomy of the appropriate compartment(s) at the time of
their initial thyroid surgery ( figure 13 and figure 14).
● Prophylactic lymphadenectomy should be performed only in the following situations:
• For patients with medullary thyroid cancer, the central compartment (level VI) nodes should be removed
prophylactically. (See "Medullary thyroid cancer: Surgical treatment and prognosis", section on 'Surgical approach'.)
• For patients with papillary thyroid cancer, a prophylactic central neck lymphadenectomy can be performed in patients
with large (≥4 cm) tumors or extrathyroidal extension. Thyroidectomy can be performed without central
lymphadenectomy in patients who have small (<4 cm) tumors without extrathyroidal extension or lymph node
involvement. This approach resulted in a local recurrence rate of only 5 percent [46]. A 2022 systematic review and
meta-analysis of five randomized trials of clinically node-negative papillary thyroid cancer found no difference in the
rates of locoregional recurrence, hypoparathyroidism, recurrent laryngeal nerve injury, and bleeding between total
thyroidectomy alone and total thyroidectomy plus prophylactic central neck dissection [47]. (See "Differentiated thyroid
cancer: Surgical treatment", section on 'Approach to lymph node dissection'.)
● Since follicular thyroid cancer spreads hematogenously, and oncocytic (formerly known as Hürthle cell) thyroid cancer
rarely spreads lymphatically, there is little role for prophylactic cervical lymphadenectomy in either patient population. (See
"Differentiated thyroid cancer: Surgical treatment", section on 'Approach to lymph node dissection'.)
Parathyroid glands — Most patients have four parathyroid glands in close association with the thyroid gland. Identification
and preservation of the parathyroid glands is essential during thyroidectomy.
Parathyroid preservation — Knowledge of the surgical anatomy is important for the identification of parathyroid glands
during thyroid dissection. The superior parathyroid glands are located posterior to the RLN; the inferior parathyroid glands are
located anterior to the RLN ( figure 15). (See "Surgical anatomy of the parathyroid glands".)
To avoid injuring the parathyroid glands, the thyroid dissection should be carried out as close to the capsule as possible while
ensuring extirpation of all visible thyroid tissues. Once identified, parathyroid glands should be preserved in situ on their native
vascular pedicles. The inferior thyroid artery supplies 80 percent of the parathyroid glands. Thus, the inferior thyroid artery
must be ligated close to the thyroid capsule to avoid encroaching upon the branches supplying the parathyroid glands, which
take off more laterally ( figure 15).
Parathyroid glands should not be removed during thyroid surgery unless they are grossly invaded by a thyroid malignancy or
become severely ischemic during dissection. In the latter case, the parathyroid gland can be autotransplanted into a well-
vascularized muscle such as the strap or sternocleidomastoid muscles [48]. (See 'Parathyroid autotransplantation' below.)
Newer technology such as indocyanine green fluorescence or near-infrared autofluorescence can be used to identify
parathyroid glands and assess parathyroid viability to guide autotransplantation. Advances in the field of near-infrared
autofluorescence technology for the identification and localization of parathyroid glands led to US Food and Drug
Administration approval of two near-infrared fluorescence detection devices. While additional validation studies are required,
better identification and localization of parathyroid glands may lead to a decrease in postoperative hypoparathyroidism [49-51].
(See 'Hypocalcemia/hypoparathyroidism' below.)
Parathyroid enlargement — One or more enlarged parathyroid glands can be incidentally found during thyroid surgery in
normocalcemic patients. Management depends upon the number of glands that are enlarged:
● Resection of a single incidentally encountered enlarged parathyroid gland is usually appropriate [52]. An intraoperative
parathyroid hormone (PTH) level should be obtained, if possible, to document occult hyperparathyroidism before the
enlarged gland is resected. If an abnormal gland is resected, a postoperative calcium and/or PTH level should also be
obtained to document adequate resection of presumed parathyroid disease.
● If all four parathyroid glands appear enlarged and the patient is known to be normocalcemic and have normal renal
function, vitamin D deficiency should be suspected. Resection of the glands is not recommended.
Parathyroid autotransplantation — A normal-sized parathyroid gland of uncertain viability or an intracapsular/intrathyroidal

gland that cannot be sustained by its native vascular pedicle should be autotransplanted into the ipsilateral strap or

sternocleidomastoid muscle. In healthy muscle, parathyroid cells can stimulate neovascularization by releasing vascular
endothelial growth factor [53]. The technique of parathyroid autotransplantation is described in detail in another topic. (See
"Parathyroidectomy in end-stage kidney disease", section on 'Creating an autograft'.)
Autotransplantation should not be performed if a parathyroid gland has obvious tumor involvement. Before transplantation,
frozen section of a small portion of the gland may be performed to ensure that the tissue is indeed of parathyroid origin, rather
than of a metastatic lymph node or a portion of the thyroid gland. Fine-needle aspiration followed by rapid intraoperative PTH
measurement of the aspirate is another way to confirm parathyroid tissue. (See 'Intraoperative frozen section analysis' below
and "Intraoperative parathyroid hormone assays", section on 'Identifying parathyroid tissue'.)
Optional techniques and equipment — Intraoperative nerve monitoring and intraoperative frozen section analysis are two
optional techniques that can be used to augment thyroid surgery. Drains and vessel sealing devices are optional equipment
that can be used to facilitate thyroid surgery.
Intraoperative nerve monitoring — Intraoperative nerve monitoring (IONM) has been advocated with the goal of reducing
the rate of RLN injury. Although its routine use remains controversial [6], it could potentially assist in the identification,
dissection, and prediction of postoperative function of the RLN [54].
Techniques of nerve monitoring — The two main components of IONM are nerve stimulation and assessment of vocal
fold response to nerve stimulation.
Nerve stimulation — The RLN can be stimulated with a low-voltage electric current delivered by a handheld probe
(intermittent stimulation) or an electrode attached to the ipsilateral vagus nerve (intermittent or continuous stimulation).
Continuous stimulation could alert the surgeon to an impending nerve injury earlier than intermittent stimulation. However,
continuous IONM has the disadvantages of potentially causing vagal neurapraxia (if the electrode dislodges) or hemodynamic
instability (eg, cardiac arrest) secondary to increased parasympathetic (vagal) tone [55]. It also requires dissection of structures
(eg, vagus nerve) outside of the typical operative field, although a transcutaneous method of vagal stimulation for IONM during
endocrine surgery has been reported [56].

Vocal fold response — The vocal fold response to nerve stimulation is most commonly measured by a laryngeal
surface electrode system built into or attached to the endotracheal tube [57-59], which is positioned at a level that enables the
vocal cords to come into contact with the electrodes [60].
During surgery, the vocal fold response to nerve stimulation is displayed on a nerve monitor as auditory or visual
electromyographic (EMG) signals. Changes in the pattern of EMG signals, which can occur with retraction of the gland,
dissection of surrounding tissues, or dissection of the RLN itself, can alert the surgeon to possible nerve irritation [57,58].
Because vocal fold response is measured by EMG activities, only short-acting muscle relaxants, such as succinylcholine, should
be used during induction of anesthesia when IONM is employed. No paralytic agents should be used after induction to prevent
interference with obtaining an EMG signal.
Efficacy of nerve monitoring — Regardless of whether IONM is used during endocrine surgery, surgeons should exercise
the same vigilance with surgical techniques to avoid RLN injury. When IONM is used, it is to augment, rather than circumvent,
the need for meticulous surgical techniques, including intraoperative visual identification of the RLN.
Most studies examining the utility of IONM have been observational; the few randomized trials were small and underpowered.
A 2019 Cochrane systematic review and meta-analysis of five trials found no advantage or disadvantage for IONM in either
permanent (relative risk 0.77, 95% CI 0.33-1.77) or transient RLN palsy (relative risk 1.25; 95% CI 0.45-3.47), when compared with
visual nerve identification [61]. A 2022 meta-analysis of eight trials similarly found no improvement with IONM in either
permanent (IONM 0.5 percent versus visual nerve identification 0.6 percent, p = 0.57) or transient (1.5 versus 2.1 percent, p =
0.11) RLN injury, although there was a nonstatistically significant reduction in overall RLN injury (3.2 versus 2.3 percent, p =
0.069) [62].
Existing data do not support that the routine use of IONM reduces the incidence of RLN injury [59,60,63-68]. IONM, however,
may be beneficial in procedures that are either high risk or performed by low-volume surgeons [59,69-71]. High-risk procedures
in this context typically include reoperations and those performed for thyroid cancers or goiters (retrosternal or toxic).
During planned total thyroidectomy, after completion of the initial lobectomy if IONM results suggest loss of function, the
surgeon may consider stopping the operation for possible completion at a later date [6].

Intraoperative frozen section analysis — In contemporary practice, frozen section analysis is no longer widely used and is
only reserved for a few situations in which it could have an impact on surgical decision making [72]:
● To diagnose thyroid malignancies intraoperatively when the preoperative cytology was atypical or suspicious, thus
potentially informing the need for a completion thyroidectomy.
● To diagnose lymph node metastasis, which may help guide the decision to perform a therapeutic central compartment
neck dissection.
● To confirm parathyroid tissue [73].
Drains — Routine drain placement after thyroid surgery is not necessary [74,75]. A meta-analysis of 11 randomized trials
found no significant difference in the incidences of hematoma or seroma formation between routine drainage and no drainage
[75].
However, if the thyroid is very large, the dissection is extensive, or the thyroid bed is persistently oozing, a closed suction drain
can be placed to prevent fluid collection [75]. The drain can be removed safely without concern for fluid reaccumulation when
the output is serous and decreasing in volume.
Vessel sealing devices — Various vessel sealing systems, such as the harmonic scalpel and LigaSure, have been employed
successfully in thyroid surgery [76]. The decision to use a vessel sealing device and the choice of the device are based on
surgeon and hospital preference [77]. However, just like monopolar electrocautery, vessel sealing devices should not be used
within 3 to 5 mm of the RLN to avoid injury.
In a propensity score matched study of over 6500 procedures, the use of a vessel sealing device was associated with a
decreased rate of neck hematoma (odds ratio 2.33, 95% CI 1.55-3.49) but no increase in the rate of RLN injuries compared with
conventional hemostasis [78].
Minimally invasive thyroid surgery — In general, remote-access thyroidectomy procedures are controversial and should only
be performed in carefully selected patients and by surgeons experienced in the approach [6].

● Endoscopic thyroidectomy – Endoscopic or endoscopic-assisted thyroidectomy is also termed minimally invasive video-
assisted thyroidectomy (MIVAT). One approach of MIVAT employs small conventional retractors and 2 mm dissecting
instruments placed through a small incision in the central neck 2 cm above the sternal notch [79,80]. Hemostasis is
achieved by using a harmonic scalpel [79]. Matched comparisons between endoscopic-assisted and conventional
thyroidectomy in patients with low- to intermediate-risk papillary thyroid carcinoma showed comparable surgical and
oncologic outcomes [80,81]. The main advantage of MIVAT over conventional thyroidectomy is that of a smaller incision.
MIVAT has also been performed via transaxillary, retroauricular, and even transoral (experimental) approaches. These
alternative approaches do not require a cervical incision [82].
● Robotic surgery – Minimally invasive thyroid surgery can be performed with or without robotic assistance. The robotic
technology allows for improved maneuverability of the endoscopic instruments and better ergonomics for the surgeon.
However, robotic surgery is associated with a steep learning curve, a significantly longer operating room time, and a
higher cost compared with conventional thyroidectomy or minimally invasive thyroid surgery performed without robotic
assistance.
Robotic-assisted minimally invasive thyroid surgery is investigational and can be performed via transoral or transaxillary
routes in a select subset of patients [83]. In a meta-analysis, robotic thyroidectomy was as safe as open thyroidectomy and
was associated with less blood loss, a lower level of swallowing impairment, and better cosmetic satisfaction [84]. The
oncologic outcomes for those who have thyroid cancer, however, remain to be determined. In addition, use of the robotic
platform for thyroidectomy remains an off-label use of the device.
POSTOPERATIVE CARE
Inpatient versus outpatient surgery — After thyroid surgery, patients may be admitted for overnight observation to manage
pain, nausea, or hypocalcemia and to monitor for hematoma formation. Select patients can undergo outpatient thyroid surgery
if it is performed by experienced surgeons [85]. In a series of 1168 thyroidectomies, nearly 20 percent were performed as
outpatient procedures, mostly by high-volume surgeons at high-volume centers [86]. In that series, the readmission rate after
outpatient surgery was comparable to that of inpatient surgery (1.4 versus 2.4 percent).

Pain control — After thyroidectomy, pain is generally reported as minimal in patients who receive preoperative education
about the issue. Counseling together with nonopioid (nonsteroidal) and nonpharmacologic therapies should be the first-line
management strategy, and if opioids are provided, the lowest effective dose of immediate-release opioids (<10 oral morphine
equivalents) should be prescribed [6]. In a trial of 95 patients undergoing thyroid surgery, those treated with nonopioid
analgesia (acetaminophen and ibuprofen) had similar pain scores to those treated with opioids up to the first postoperative visit
[87]. In another study, over half of the patients did not take opioid medications after cervical endocrine surgery, even though
most were prescribed them [88].
Thyroid hormone supplementation — The requirement for thyroid hormone supplementation after thyroid surgery depends
upon the patient's diagnosis (benign versus malignant disease) and the extent of their resection (total thyroidectomy versus
thyroid lobectomy).
Benign disease except hyperthyroidism — Patients who undergo total thyroidectomy for benign disease are typically started
on a daily dose of levothyroxine at approximately 1.6 mcg/kg body weight after surgery. Patients over 65 years should be
started at a lower dose; men may require higher doses than women. Approximately six weeks after starting levothyroxine,
serum thyroid-stimulating hormone (TSH) should be measured and levothyroxine dose adjusted to keep TSH in the normal
range. After that, annual TSH measurements are sufficient for patients who are clinically doing well. Those who display
symptoms of either hypo- or hyperthyroidism require further evaluation and adjustment of their medications.
Patients who undergo thyroid lobectomy for benign disease are not routinely started on levothyroxine after surgery, but
approximately one-third of them may require levothyroxine supplementation to maintain a normal TSH level. The possibility of
permanent hypothyroidism should be discussed with patients prior to any thyroid surgery, including thyroid lobectomy [89]. A
TSH level should be obtained approximately six weeks after surgery to determine the need for thyroid hormone replacement.
(See "Treatment of primary hypothyroidism in adults".)
Hyperthyroidism — Patients who undergo thyroidectomy for hyperthyroidism require special attention perioperatively. The
postoperative management of these patients is discussed in detail elsewhere. (See "Surgical management of hyperthyroidism",
section on 'Postoperative management'.)

Malignant disease — The requirement for thyroid hormone replacement in patients who undergo total thyroidectomy for
malignant disease depends on the stage of their disease, the aggressiveness of the cancer, and the need for radioiodine
ablation (RAI) postoperatively. (See "Differentiated thyroid cancer: Surgical treatment", section on 'Postoperative thyroid
hormone therapy'.)
● Patients who are scheduled to receive RAI within two to three weeks of surgery may be discharged home without any
thyroid hormone replacement. Thyroid hormone withdrawal raises the TSH level, which stimulates radioiodine uptake and
improves the efficacy of RAI. Alternatively, patients may be started on levothyroxine in anticipation of use of recombinant
human thyrotropin (rhTSH) prior to RAI.
● Patients who are not scheduled to receive RAI within two or three weeks of surgery may be discharged on liothyronine
(T3). Liothyronine is a short-acting thyroid hormone, the level of which can be manipulated to optimize the energy level of
the patient. Based on the patient's weight and age, the starting dose of liothyronine is typically 10 to 25 mcg twice a day.
Symptoms of dizziness, palpitation, or insomnia may require immediate lowering of the liothyronine dose. Liothyronine is
discontinued one to two weeks prior to RAI treatment to induce thyroid hormone withdrawal. (See "Differentiated thyroid
cancer: Radioiodine treatment", section on 'Patient preparation'.)
● Another option for patients who have a low-risk differentiated thyroid cancer is to be started on levothyroxine immediately
after surgery, followed by recombinant human thyrotropin (rhTSH) just prior to RAI to activate TSH receptors [90]. (See
"Differentiated thyroid cancer: Radioiodine treatment", section on 'Recombinant human TSH'.)
After RAI, patients should be maintained on levothyroxine at a daily dose of approximately 1.6 mcg/kg body weight. The actual
target of TSH suppression will depend on the patient's age as well as the stage and aggressiveness of the cancer [91]. (See
"Differentiated thyroid cancer: Overview of management", section on 'Thyroid hormone suppression'.)
Calcium supplementation — Calcium supplementation after thyroid surgery is typically given orally as calcium carbonate,
1250 to 2500 mg daily total, divided in two to four doses, with the starting dose adjusted and eventually tapered off based on
symptoms and/or calcium levels. Patients who take a proton pump inhibitor or have had gastric bypass surgery should take
calcium citrate instead due to their lack of gastric acid, which is required for optimal absorption of calcium carbonate.

Intravenous calcium is occasionally required in patients with persistently low calcium levels and symptoms despite oral
supplementation. In such patients, peripheral intravenous (IV) infusion sites should be carefully monitored because infiltration
of a solution containing calcium can result in soft tissue loss. Patients can be discharged on oral calcium supplementation when
their hypocalcemic symptoms resolve and their serum calcium levels stabilize at ≥7.8 mg/dL. (See "Treatment of hypocalcemia".)
Persistent hypocalcemia should also prompt measurement of serum magnesium with repletion if necessary. In a large database
study, magnesium disorders were associated with the greatest odds of short- and long-term postoperative hypocalcemia [92].
In addition to calcium, patients with very low or undetectable parathyroid hormone (PTH) levels may need 1,25-
dihydroxyvitamin D (calcitriol) to adequately absorb calcium. In such patients, calcitriol can be started prior to thyroid surgery
and gradually tapered postoperatively according to the PTH and/or calcium levels [93]. Patients should continue to be
monitored for both hypocalcemia (as calcitriol can take 24 to 48 hours to achieve maximal effect) and potential resultant
hypercalcemia. If discharged on calcitriol, repeat laboratory tests within three to five days of discharge should be obtained. (See
"Treatment of hypocalcemia".)
While all symptomatic hypocalcemia patients require treatment with intravenous or oral calcium, asymptomatic patients may or
may not receive calcium supplementation at the surgeon's discretion:
● Some surgeons only prescribe calcium supplementation to patients with low postoperative serum calcium levels and/or
low PTH [94-97]. (See "Clinical manifestations of hypocalcemia" and "Diagnostic approach to hypocalcemia" and
"Diagnostic approach to hypocalcemia", section on 'Serum PTH concentrations'.)
• In a study of 120 patients who underwent total or near-total thyroidectomy, low total (<7.2 mg/dL) or ionized (<1.0
mmol/L) serum calcium level at 16 hours postoperatively identified 94.5 percent of patients who needed calcium
supplementation [95].
• In a prospective study of 143 patients undergoing total thyroidectomy, the 112 patients who had a PTH level ≥10 pg/mL
on the first postoperative day were discharged without calcium supplementation; only 10 percent developed
hypocalcemic symptoms [94]. By contrast, almost one-half of the other 31 patients who had postoperative day 1 PTH
level <10 pg/mL developed hypocalcemia despite some receiving calcium supplementation.

• In another prospective observational study of 123 patients undergoing total or completion thyroidectomy, an 80
percent decrease in intact PTH (iPTH) level postoperatively compared with preoperatively was 100 percent sensitive in
predicting clinical hypocalcemia, whereas a postoperative iPTH level of <3 pg/mL was 100 percent specific. Thus,
patients with a <80 percent decrease in iPTH, those with an iPTH decrease of ≥80 percent but a postoperative iPTH ≥3
pg/mL, and those with a postoperative iPTH level of <3 pg/mL are at very low, intermediate, and very high risk of
developing hypocalcemia, respectively [98].
• However, a 2018 systematic review found that the existing literature regarding the use of PTH levels to predict post-
thyroidectomy hypocalcemia is extremely heterogeneous. With a false negative rate as high as 54 percent, and a false
positive rate as high as 70 percent, a single PTH threshold may not be a reliable measure of hypocalcemia [99].
● Other surgeons prescribe calcium supplementation routinely to all patients after thyroidectomy to prevent symptoms of
hypocalcemia [100]. In a small randomized trial of 79 patients undergoing total thyroidectomy, routine administration of
oral calcium and vitamin D reduced both the incidence and severity of hypocalcemia symptoms [93]. In a meta-analysis of
15 studies, routine supplementation with calcium and vitamin D3 after thyroidectomy was associated with a lower risk of
symptomatic hypocalcemia (risk difference -0.25, 95% CI -0.32 to -0.18) and biochemical hypocalcemia (risk difference
-0.24, 95% CI -0.31 to -0.17) compared with treatment based on measured calcium levels [101].
Follow-up — A follow-up visit should be scheduled in one to two weeks after surgery to:
● Evaluate and manage incisional healing.

● Evaluate the patient for any unusual voice changes, subtle hypocalcemic symptoms, and overall recovery.
● Adjust doses of medications, including those of thyroid hormone replacement and calcium/vitamin D supplementation.
● Review surgical pathology results.
● Discuss plans for further treatment or observation.
● Coordinate multidisciplinary care for patients with thyroid cancer [102].
COMPLICATIONS

Complications of thyroid surgery include wound seroma or hematoma, hypocalcemia due to hypoparathyroidism, hoarseness
or change in voice, vocal cord paresis or paralysis due to nerve injury, Horner syndrome, chyle fistula, tracheal or esophageal
injury, and dysphagia.
An Italian study of 14,934 patients who underwent thyroid surgery (21 percent lobectomy, 64 percent total thyroidectomy, 9
percent subtotal thyroidectomy, 6 percent reoperation) reported that hemorrhage occurred in 1.2 percent, hypoparathyroidism
in 10 percent (8.3 percent transient, 1.7 percent permanent), superior laryngeal nerve injury in 3.7 percent, recurrent laryngeal
nerve injury in 3.4 percent (2 percent transient, 1 percent unilateral permanent, 0.4 percent bilateral permanent), and dysphagia
in 1.4 percent of patients [38].
In an international study of 2325 patients who underwent surgery for differentiated thyroid cancer, 25.8 percent reported voice
changes persisting for longer than three months, 12.7 percent had an abnormal voice handicap index-10 score (VHI-10; which
quantifies 10 psychosocial consequences of voice disorder), and 4.7 percent had initial detectable vocal fold motion
abnormalities on laryngoscopy [103]. However, this study likely identified transient voice disorders, as permanent dysfunction is
defined as lasting for 6 to 12 months.
The reported rates for each complication vary by geography but are generally somewhat considerably lower in the United States
(US) than in other countries. Additionally, complication rates, particularly those of nerve injury, hypoparathyroidism, and
dysphagia, are also lower in patients operated on by high-volume surgeons and/or at high-volume centers [104-110]. One study
found that the likelihood of experiencing a complication after total thyroidectomy decreased when the surgeon performed >25
total thyroidectomies per year [110].
In a study of more than 8000 patients in the US Collaborative Endocrine Surgery Quality Improvement Program (CESQIP), the
rates of all emergency room visits and all hospital readmissions were 3.4 and 2.3 percent, respectively [111]. Hypocalcemia was
the reason for 22 percent of emergency room visits and 36 percent of the readmissions. Severe obesity, long surgery, and
recurrent laryngeal nerve injury were risk factors for return visits.
Hematoma — Postoperative hematoma is a rare but potentially fatal complication of thyroid surgery [38,112-114]. In a
retrospective review of 150,012 patients, 1.25 percent developed a postoperative hematoma, and in other studies the rate
ranged from 0.7 to 1.5 percent [6,115]. The mortality rate was much higher with a hematoma (1.34 versus 0.32 percent) [114].

To prevent postoperative bleeding and hematoma formation, patients should stop all anticoagulants before surgery;
hemostasis must be meticulously maintained during surgery. Additionally, the following conditions have been associated with
postoperative hematoma formation by multivariate analyses [114,116]:
● Inflammatory thyroid conditions (odds ratio [OR] 1.59, 95% CI 1.23-2.06)
● Partial thyroidectomy (OR 1.69, 95% CI 1.20-2.37)
● Chronic renal disease (predisposition to bleeding disorders; OR 1.8, 95% CI 1.08-3.03)
● Bleeding disorders (OR 3.38, 95% CI 1.76-6.50) [114]
● Graves' disease (OR 2.43, 95% CI 1.22-4.85 [116]; OR 1.58, 95% 1.09-2.31 [117])
● Benign pathology (OR 2.22, 95% CI 1.35-3.57)
● Antiplatelet/anticoagulation medications (OR 2.12, 95% CI 1.10-4.13)
● Use of a hemostatic agent (OR 1.97, 95% CI 1.21-3.18)
● Use of a drain (OR 2.79, 95% CI 1.68-4.65) [116]
A cervical hematoma is characteristically a large, tense, firm, immobile anterior or lateral cervical swelling under the incision.
After surgery, the surgical team should routinely examine the patient for signs or symptoms of a hematoma including wound
inspection, pain scoring, as well as being aware of more subtle signs such as discomfort, agitation, anxiety, or difficulty in
breathing [118].
Any hematoma that causes airway compromise should be opened at the bedside, for which a post-thyroid surgery emergency
box containing essential surgical tools should always be available, including during transfer. We recommend using the SCOOP
approach (skin exposure; cut sutures; open skin; open muscles [superficial and deep] layers; pack wound), before the patient is
further evaluated and returned to the operating room for formal exploration of a potential source [118].

A post-thyroidectomy hematoma in a patient without immediate concern for airway compromise should be evacuated in the
operating room. In a retrospective study of 207 patients who developed a hematoma after thyroidectomy, 79 percent required
operating room evacuation within 24 hours of the original surgery. Patients diagnosed with a hematoma should be kept awake
and promptly transported to the operating room for evacuation. In the operating room, in most cases the patient's neck should
be cleansed with antiseptics, the incision opened, and blood from the hematoma evacuated all prior to intubation, as a large
cervical hematoma might make intubation more difficult by compressing the larynx.
Once the airway is secured by intubation, the hematoma should be completely evacuated and hemostasis established with
meticulous techniques. The hematoma is usually in the paratracheal area. Thus, the strap muscle closure should be reopened to
allow inspection and evacuation of this compartment. The recurrent laryngeal nerves (RLNs) and parathyroid glands should be
carefully preserved to avoid a secondary injury; blind use of electrocautery near the ligament of Berry must be avoided.
Placement of a drain facilitates prompt evacuation of serous fluid that may accumulate in the bed of the hematoma. Patients
may require overnight intubation to allow supraglottic edema to subside before extubation.
Seroma — Wound seromas are typically superficial, mobile, and likely to resolve without any intervention.
Hypocalcemia/hypoparathyroidism — Hypocalcemia is one of the most common complications of thyroidectomy [119].

Symptoms of hypocalcemia range from mild (eg, paresthesias around the lips, mouth, hands, and feet) or moderate (eg, muscle
twitches or frank cramps) to severe (eg, trismus or tetany). (See "Clinical manifestations of hypocalcemia".)
While all patients with symptomatic hypocalcemia require oral calcium and some may need to be managed with additional
intravenous calcium or calcitriol, asymptomatic patients may or may not need calcium supplementation (at the surgeon's
discretion). (See 'Calcium supplementation' above.)
Transient hypoparathyroidism has been reported in 0.3 to 49 percent of patients after thyroidectomy; up to 13 percent of post-
thyroidectomy hypoparathyroidism becomes permanent [119]. However, the clinical definition of hypoparathyroidism is
controversial, which limits the analysis of its rates after thyroidectomy. We counsel our patients that the risk of permanent
hypoparathyroidism after a total thyroidectomy by an experienced surgeon in the United States is approximately 2 percent.

Intraoperative indocyanine green (ICG) angiography has been used in thyroid surgery to predict postoperative
hypoparathyroidism. In a randomized trial, none of the 146 patients who had at least one well-perfused parathyroid gland on
ICG angiography developed postoperative hypocalcemia with or without laboratory tests and calcium supplementation, which
did not affect surgical results. By contrast, 11 of 50 patients who did not have any well-perfused parathyroid gland on ICG
angiography developed hypocalcemia on postoperative day 1, and 6 on postoperative days 10 to 15 [120].
Parathyroid tissue, when submitted to near-infrared stimulation, emits a spontaneous autofluorescent signal termed near-
infrared-induced autofluorescence (NIRAF). In a European trial (PARAFLUO) of 245 patients undergoing total thyroidectomy, the
use of NIRAF intraoperative imaging of the parathyroids resulted in a decrease in the rate of temporary postoperative
hypocalcemia (9 versus 22 percent), parathyroid autotransplantation (4 versus 16 percent), and inadvertent parathyroid
resection (3 versus 14 percent) [121].
Hoarseness — Hoarseness is common after thyroid surgery. Transient hoarseness that resolves spontaneously in 24 to 48
hours is typically due to vocal cord edema caused by endotracheal intubation. Persistent or severe hoarseness is rare and can
be caused by arytenoid dislocation or vocal cord dysfunction from a nerve injury [122-124].
Arytenoid dislocation is an unusual consequence of endotracheal intubation that can cause hoarseness, vocal fatigue, and
dysphagia. Arytenoid dislocation should be promptly treated with reduction and repositioning of the arytenoid cartilage [125].
Symptomatic voice changes generally improve after the immediate postoperative period. Hoarseness, uncontrolled coughing
when talking, dyspnea that persists for more than 24 to 48 hours after surgery, or aspiration pneumonia should raise suspicion
for possible vocal cord motion abnormalities. Such patients should be referred promptly for direct laryngoscopy and a complete
neurolaryngeal evaluation [126].
Nerve injury/vocal cord paresis or paralysis — Nerve injury can result from the underlying thyroid disease process, surgery,
or anesthesia-related airway manipulation (eg, endotracheal intubation). Three nerves can potentially be injured during thyroid
surgery:
● Superior laryngeal nerve (SLN) – Injury to the external branch of the SLN results in voice weakness or fatigue as well as
changes to both quality and pitch of the voice [127]. (See 'Superior laryngeal nerve injury' below.)

● Recurrent laryngeal nerve – Injury to the RLN results in the ipsilateral true vocal cord being paretic or paralyzed in a
paramedian or lateral position. Intrinsic muscles of the larynx, except the cricothyroid muscle, are denervated, and the
patient may have swallowing difficulties and an increased aspiration risk. (See 'Recurrent laryngeal nerve injury' below.)
● Vagus nerve – High transection or injury to the vagus nerve near the carotid bulb paralyzes both the SLN and the RLN. This
can result in both sensory and motor deficits of the larynx, which are significant risk factors for aspiration.
Superior laryngeal nerve injury — Isolated SLN injury only produces vocal fatigue and subtle changes in voice quality in
timbre, pitch, and voice projection. Due in part to difficulties in accurate diagnosis, rates of SLN injury after thyroidectomy are
difficult to determine. In one study, SLN injury was seen after approximately 4 percent of thyroid surgeries [38]. Patients should
be counseled preoperatively that they may experience permanent pitch change or have permanent difficulty singing high notes
or speaking at a loud volume after surgery.
SLN injury is typically diagnosed with a complete neurolaryngeal evaluation, which could include specialized procedures such as
rigid or flexible videostroboscopy or laryngeal electromyography [126]. Aerodynamic assessment of voice production and
objective acoustic voice evaluation are also helpful in following improvement over time.
Recurrent laryngeal nerve injury — Iatrogenic injury to the RLN is one of the most concerning complications of thyroid
surgery [128]. In various studies, rates of RLN injury ranged from 0 to 7.1 percent for transient injury and 0 to 11 percent for
permanent injury; lower rates of RLN injury were achieved by higher-volume surgeons [104-106,129].
Vocal cord paresis — Typically caused by a traction injury to the RLN, vocal cord paresis is usually transient and does not
require intervention. However, referral to a voice or speech therapist can help protect the patient's voice, reduce strain, reduce
anxiety, and improve vocalization. The vocal cord should typically be reexamined at three and six months. Temporary vocal cord
paresis usually resolves by six months. If the vocal cord is immobile for longer than six months, permanent paralysis is likely.
(See 'Unilateral vocal cord paralysis' below.)
Unilateral vocal cord paralysis — RLN injury can result in the ipsilateral true vocal cord being paralyzed in a paramedian
or lateral position. Medialization of the paralyzed vocal cord improves both swallowing and phonating by allowing the
contralateral functioning vocal cord to close off the larynx. A vocal cord paralyzed in the lateral position can be temporarily

medialized by injection of fat, silicone, or collagen [130,131]. In patients with permanent deficits (persisting for more than 6 to
12 months after the initial thyroid surgery), collagen can be injected for medialization of the paralyzed vocal cord [131,132].
Early surgical medialization of a paralyzed vocal cord is indicated in patients with severe symptoms such as aspiration
pneumonia, disabling breathy hypophonia, ineffective cough, or disabling dyspnea. Patients who have mild symptoms should
undergo voice/speech therapy. Those who do not respond to voice/speech therapy after six to nine months and who
demonstrate evidence of denervation or little activity on laryngeal electromyography should undergo surgical medialization of
the paralyzed vocal cord [133].
Bilateral vocal cord paralysis — Bilateral vocal cord paralysis from injuries to both RLNs is a rare (0.4 percent of cases)
but devastating complication of total thyroidectomy that occurs most commonly with reoperations [38]. Bilateral vocal cord
paralysis is usually recognized immediately after surgery when the patient develops dyspnea and stridor upon extubation.
Immediate reintubation is usually possible, but a tracheostomy may be required if the patient cannot be orotracheally
reintubated (eg, if both vocal cords are adducted).
In patients who have permanent bilateral vocal cord paralysis, a partial posterior cordectomy using laser surgery can restore
sufficient laryngeal airflow with minimal vocal sequelae and avoid long-term tracheostomy. Bilateral vocal cord paralysis should
be managed by a multidisciplinary team for optimal outcomes [126].
Techniques of nerve repair — If an RLN injury is identified intraoperatively, nerve repair should be attempted, when feasible,
to promote synkinesis [6,134].
Injured nerves with clean, fresh edges; good hemostasis; and without tension on either end have the best chance of a
successful repair. Avulsion or cautery injuries are more difficult to repair than a sharp transection.
The surgical options include direct end-to-end anastomosis (neurorrhaphy), direct implantation of a nerve ending into the
thyroarytenoid muscle, or muscle-nerve pedicle grafting using ansa cervicalis. A fine nonabsorbable suture is typically used for
the repair.
If the transected nerve appears foreshortened, an interposition nerve graft with a diameter comparable to that of the RLN can
be used [135,136]. Commonly used interposition grafts in the neck include the ansa cervicalis nerve and the hypoglossal nerve.
The techniques of nerve repair are discussed in detail elsewhere. (See "Traumatic peripheral neuropathies", section on
'Treatment overview'.)
Dysphagia — Dysphagia is a frequent complaint both before and after thyroid surgery. The etiology of post-thyroidectomy
dysphagia is uncertain but may be related to postoperative adhesions, decreased laryngeal elevation, cricothyroid trauma or
inflammation, or perithyroidal nerve damage.
Despite an initial decline in the immediate postoperative period, patients without an RLN injury generally experience
improvement in their swallowing function at six months after surgery compared with at the preoperative baseline [137], which
may be attributed to resolution of compressive symptoms.
In one study, 47 percent of patients who underwent total thyroidectomy had swallowing complaints before surgery, 74 percent
during the first week after surgery, and only 20 percent at six months [137]. In another study, 57 percent of patients reported
swallowing problems before thyroid surgery, but only 8 percent had persistent symptoms at six months after surgery [138].
Anecdotally, incisional massage may greatly improve postoperative dysphagia.
Horner syndrome — Horner syndrome is a neurologic syndrome caused by disruption of the sympathetic pathway that
supplies the head, eye, and neck. The symptoms of Horner syndrome are miosis, ptosis, and anhidrosis. Horner syndrome is a
very rare (0.2 percent) complication of thyroidectomy that is most often associated with a lateral neck dissection [139]. The
sympathetic chain can be disrupted due to ischemic nerve damage, stretching of the cervical sympathetic chain by the retractor,
or postoperative hematoma. Injury to the sympathetic chains can be minimized with careful dissection around the prevertebral
fascia and carotid sheath. (See "Horner syndrome".)
Chyle leak — Chyle leaks or fistulas are caused by injury to the thoracic duct. Chyle leak is reported in 1.8 to 8.3 percent of
thyroidectomies. Although chyle leak occurs most often when a lateral lymph node dissection has been performed [140], it can
occur with central neck dissection as well [141]. (See "Etiology, clinical presentation, and diagnosis of chylothorax".)
Chyle leaks can lead to severe fluid and electrolyte imbalances and even death if not treated properly. They are generally
indicated by milky drainage, a bulging supraclavicular fossa, and induration or erythema of the skin. Low-output chyle leak

(<500 mL/day) can be managed conservatively with fasting [141]; high-output leaks require surgical ligation of the thoracic duct
[140].
Tracheal injury — Tracheal necrosis secondary to excessive use of cautery on or around the trachea is a rare complication of
thyroidectomy [142]. The blood supply to the upper trachea is primarily from small branches of the inferior thyroid artery, which
could be damaged during thyroid surgery. Tracheal necrosis can lead to air leak or subcutaneous emphysema and is potentially
life-threatening. Any tracheal injury requires neck reexploration and construction of a tracheostomy. (See "Tracheostomy:
Rationale, indications, and contraindications".)
Esophageal injury — While rare, esophageal and pharyngeal injury can occur with thyroid surgery. The finding of extensive
crepitus in the neck postoperatively should prompt immediate evaluation for a pharyngeal or esophageal perforation. (See
"Overview of esophageal injury due to blunt or penetrating trauma in adults".)
SOCIETY GUIDELINE LINKS
Links to society and government-sponsored guidelines from selected countries and regions around the world are provided
separately. (See "Society guideline links: Thyroid surgery".)
INFORMATION FOR PATIENTS
UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education
pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a
patient might have about a given condition. These articles are best for patients who want a general overview and who prefer
short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed.
These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and
are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your
patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the
keyword(s) of interest.)
● Basics topics (see "Patient education: Seroma (The Basics)")
SUMMARY AND RECOMMENDATIONS
● Preoperative evaluation – Thyroidectomy is usually an elective operation, and any major medical issues should be
addressed before proceeding to surgery. (See 'Preoperative evaluation and preparation' above.)
• Patients with hyperthyroidism should be medically optimized with antithyroid medications and/or a beta blocker prior
to thyroid surgery to avoid thyroid storm. (See "Surgical management of hyperthyroidism", section on 'Preoperative
preparation'.)
• Diagnostic thyroid ultrasound should be performed in all patients with a suspected malignancy, thyroid nodule,
nodular goiter, or abnormality detected on other imaging modalities. Imaging modalities such as computed
tomography (CT) or magnetic resonance imaging (MRI) should be reserved for the assessment of patients with
extensive extrathyroidal disease. (See 'Preoperative evaluation and preparation' above.)
• Preoperative laryngoscopy or laryngeal ultrasound should be performed for patients with preoperative hoarseness or
voice changes, extrathyroidal disease extension, or bulky lymphadenopathy and for all patients undergoing reoperative
surgery. (See 'Preoperative evaluation and preparation' above.)
● Intraoperative recurrent laryngeal nerve protection – Routine visual identification of the recurrent laryngeal nerve
(RLN) decreases the incidence of injury and is regarded as the standard of care in thyroid surgery. Intraoperative nerve
monitoring is an adjunctive measure that can be used to identify the nerve with the goal of reducing the risk of nerve
injury but should not be relied upon as a substitute for good surgical technique. (See 'Dissection of the thyroid gland'
above and 'Intraoperative nerve monitoring' above.)

● Intraoperative frozen section analysis – Frozen section analysis during thyroid surgery should only be employed when it
will have an impact on surgical decision making. (See 'Intraoperative frozen section analysis' above.)
● Postoperative management – The requirement for immediate thyroid hormone supplementation after thyroid surgery
depends upon the patient's diagnosis (benign versus malignant) and the extent of their resection (total thyroidectomy
versus thyroid lobectomy). (See 'Thyroid hormone supplementation' above.)
• Patients undergoing total thyroidectomy are at risk for developing transient or permanent hypoparathyroidism
postoperatively. Some surgeons prescribe calcium supplementation routinely after thyroidectomy to prevent
symptoms of hypocalcemia, whereas others do so selectively based upon postoperative serum calcium levels. Patients
should be counseled to promptly report hypocalcemic symptoms such as circumoral paresthesias. (See 'Calcium
supplementation' above.)
• Hoarseness, uncontrolled coughing when the patient is talking, dyspnea persisting for more than 24 to 48 hours after
thyroid surgery, or aspiration pneumonia should raise suspicion of potential vocal cord paralysis as a result of an RLN
injury. Such patients should be evaluated promptly, including direct laryngoscopy. (See 'Hoarseness' above and 'Nerve
injury/vocal cord paresis or paralysis' above.)
Use of UpToDate is subject to the Terms of Use.
REFERENCES
1. Rogers-Stevane J, Kauffman GL Jr. A historical perspective on surgery of the thyroid and parathyroid glands. Otolaryngol
Clin North Am 2008; 41:1059.
2. Loyo M, Tufano RP, Gourin CG. National trends in thyroid surgery and the effect of volume on short-term outcomes.
Laryngoscope 2013; 123:2056.
3. Kandil E, Noureldine SI, Abbas A, Tufano RP. The impact of surgical volume on patient outcomes following thyroid surgery.
Surgery 2013; 154:1346.

4. Adkisson CD, Howell GM, McCoy KL, et al. Surgeon volume and adequacy of thyroidectomy for differentiated thyroid
cancer. Surgery 2014; 156:1453.
5. Adam MA, Thomas S, Youngwirth L, et al. Is There a Minimum Number of Thyroidectomies a Surgeon Should Perform to
Optimize Patient Outcomes? Ann Surg 2016.
6. Patel KN, Yip L, Lubitz CC, et al. The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical
Management of Thyroid Disease in Adults. Ann Surg 2020; 271:e21.
7. Mirallié E, Rigaud J, Mathonnet M, et al. Management and prognosis of metastases to the thyroid gland. J Am Coll Surg
2005; 200:203.
8. Nixon IJ, Whitcher M, Glick J, et al. Surgical management of metastases to the thyroid gland. Ann Surg Oncol 2011; 18:800.
9. Nixon IJ, Coca-Pelaz A, Kaleva AI, et al. Metastasis to the Thyroid Gland: A Critical Review. Ann Surg Oncol 2017; 24:1533.
10. Patel KN, Yip L, Lubitz CC, et al. Executive Summary of the American Association of Endocrine Surgeons Guidelines for the
Definitive Surgical Management of Thyroid Disease in Adults. Ann Surg 2020; 271:399.
11. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS,
Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and
differentiated thyroid cancer. Thyroid 2009; 19:1167.
12. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients
with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on
Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1.
13. Stang MT, Armstrong MJ, Ogilvie JB, et al. Positional dyspnea and tracheal compression as indications for goiter resection.
Arch Surg 2012; 147:621.
14. Ukkat J, Gimm O, Brauckhoff M, et al. Single center experience in primary surgery for medullary thyroid carcinoma. World J
Surg 2004; 28:1271.
15. Schulte KM, Machens A, Fugazzola L, et al. The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare
intracellular RET mutation S891A. J Clin Endocrinol Metab 2010; 95:E92.

16. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management
guidelines of the American Thyroid Association. Thyroid 2009; 19:565.
17. Wong KP, Lang BH, Ng SH, et al. A prospective, assessor-blind evaluation of surgeon-performed transcutaneous laryngeal
ultrasonography in vocal cord examination before and after thyroidectomy. Surgery 2013; 154:1158.
18. Steurer M, Passler C, Denk DM, et al. Advantages of recurrent laryngeal nerve identification in thyroidectomy and
parathyroidectomy and the importance of preoperative and postoperative laryngoscopic examination in more than 1000
nerves at risk. Laryngoscope 2002; 112:124.
19. Zanocco K, Kaltman DJ, Wu JX, et al. Cost Effectiveness of Routine Laryngoscopy in the Surgical Treatment of Differentiated
Thyroid Cancer. Ann Surg Oncol 2018; 25:949.
20. Shaha AR. Revision thyroid surgery - technical considerations. Otolaryngol Clin North Am 2008; 41:1169.
21. Randolph GW, Kamani D. The importance of preoperative laryngoscopy in patients undergoing thyroidectomy: voice, vocal
cord function, and the preoperative detection of invasive thyroid malignancy. Surgery 2006; 139:357.
22. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of
Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26:1343.
23. Erbil Y, Ozluk Y, Giriş M, et al. Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients
with Graves' disease. J Clin Endocrinol Metab 2007; 92:2182.
24. Oltmann SC, Brekke AV, Schneider DF, et al. Preventing postoperative hypocalcemia in patients with Graves disease: a
prospective study. Ann Surg Oncol 2015; 22:952.
25. Goldenberg D, Ferris RL, Shindo ML, et al. Thyroidectomy in patients who have undergone gastric bypass surgery. Head
Neck 2018; 40:1237.
26. Lefevre JH, Tresallet C, Leenhardt L, et al. Reoperative surgery for thyroid disease. Langenbecks Arch Surg 2007; 392:685.
27. Levin KE, Clark AH, Duh QY, et al. Reoperative thyroid surgery. Surgery 1992; 111:604.
28. Tan MP, Agarwal G, Reeve TS, et al. Impact of timing on completion thyroidectomy for thyroid cancer. Br J Surg 2002;
89:802.

29. Uruno T, Masaki C, Suzuki A, et al. Antimicrobial prophylaxis for the prevention of surgical site infection after thyroid and
parathyroid surgery: a prospective randomized trial. World J Surg 2015; 39:1282.
30. Avenia N, Sanguinetti A, Cirocchi R, et al. Antibiotic prophylaxis in thyroid surgery: a preliminary multicentric Italian
experience. Ann Surg Innov Res 2009; 3:10.
31. Leaper DJ, Melling AG. Antibiotic prophylaxis in clean surgery: clean non-implant wounds. J Chemother 2001; 13 Spec No
1:96.
32. Gagliardi AR, Fenech D, Eskicioglu C, et al. Factors influencing antibiotic prophylaxis for surgical site infection prevention in
general surgery: a review of the literature. Can J Surg 2009; 52:481.
33. Fry DE. Surgical site infections and the surgical care improvement project (SCIP): evolution of national quality measures.
Surg Infect (Larchmt) 2008; 9:579.
34. Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup, et al. Antimicrobial prophylaxis for
surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38:1706.
35. Braxton CC, Gerstenberger PA, Cox GG. Improving antibiotic stewardship: order set implementation to improve
prophylactic antimicrobial prescribing in the outpatient surgical setting. J Ambul Care Manage 2010; 33:131.
36. Worni M, Schudel HH, Seifert E, et al. Randomized controlled trial on single dose steroid before thyroidectomy for benign
disease to improve postoperative nausea, pain, and vocal function. Ann Surg 2008; 248:1060.
37. Lang BH, Ng SH, Wong KP. Pain and surgical outcomes with and without neck extension in standard open thyroidectomy: a
prospective randomized trial. Head Neck 2015; 37:407.
38. Rosato L, Avenia N, Bernante P, et al. Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients
operated on in Italy over 5 years. World J Surg 2004; 28:271.
39. Brunaud L, Zarnegar R, Wada N, et al. Incision length for standard thyroidectomy and parathyroidectomy: when is it
minimally invasive? Arch Surg 2003; 138:1140.
40. Waseem T, Ahmed SZ, Baig H, et al. Truncal vs Branch Ligation of Inferior Thyroid Arteries in Total Thyroidectomy: Does It
Affect Postoperative Hypoparathyroidism? Otolaryngol Head Neck Surg 2021; 164:759.

41. Barczyński M, Konturek A, Hubalewska-Dydejczyk A, et al. Five-year follow-up of a randomized clinical trial of total
thyroidectomy versus Dunhill operation versus bilateral subtotal thyroidectomy for multinodular nontoxic goiter. World J
Surg 2010; 34:1203.
42. Wilhelm SM, McHenry CR. Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves' disease in
the United States. World J Surg 2010; 34:1261.
43. Bilimoria KY, Zanocco K, Sturgeon C. Impact of surgical treatment on outcomes for papillary thyroid cancer. Adv Surg 2008;
42:1.
44. Tuttle RM, Fagin JA, Minkowitz G, et al. Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During
Active Surveillance. JAMA Otolaryngol Head Neck Surg 2017; 143:1015.
45. Tuttle RM, Zhang L, Shaha A. A clinical framework to facilitate selection of patients with differentiated thyroid cancer for
active surveillance or less aggressive initial surgical management. Expert Rev Endocrinol Metab 2018; 13:77.
46. Grant CS, Stulak JM, Thompson GB, et al. Risks and adequacy of an optimized surgical approach to the primary surgical
management of papillary thyroid carcinoma treated during 1999-2006. World J Surg 2010; 34:1239.
47. Alsubaie KM, Alsubaie HM, Alzahrani FR, et al. Prophylactic Central Neck Dissection for Clinically Node-Negative Papillary
Thyroid Carcinoma. Laryngoscope 2022; 132:1320.
48. Olson JA Jr, DeBenedetti MK, Baumann DS, Wells SA Jr. Parathyroid autotransplantation during thyroidectomy. Results of
long-term follow-up. Ann Surg 1996; 223:472.
49. Wang B, Zhu CR, Liu H, et al. The Ability of Near-Infrared Autofluorescence to Protect Parathyroid Gland Function During
Thyroid Surgery: A Meta-Analysis. Front Endocrinol (Lausanne) 2021; 12:714691.
50. Kim DH, Lee S, Jung J, et al. Near-infrared autofluorescence-based parathyroid glands identification in the thyroidectomy or
parathyroidectomy: a systematic review and meta-analysis. Langenbecks Arch Surg 2022; 407:491.
51. Solórzano CC, Thomas G, Berber E, et al. Current state of intraoperative use of near infrared fluorescence for parathyroid
identification and preservation. Surgery 2021; 169:868.
52. Carnaille BM, Pattou FN, Oudar C, et al. Parathyroid incidentalomas in normocalcemic patients during thyroid surgery.
World J Surg 1996; 20:830.

53. Carter WB, Uy K, Ward MD, Hoying JB. Parathyroid-induced angiogenesis is VEGF-dependent. Surgery 2000; 128:458.
54. Randolph GW, Dralle H, International Intraoperative Monitoring Study Group, et al. Electrophysiologic recurrent laryngeal
nerve monitoring during thyroid and parathyroid surgery: international standards guideline statement. Laryngoscope
2011; 121 Suppl 1:S1.
55. Terris DJ, Chaung K, Duke WS. Continuous Vagal Nerve Monitoring is Dangerous and Should not Routinely be Done During
Thyroid Surgery. World J Surg 2015; 39:2471.
56. Suh I, Yingling C, Randolph GW, Duh QY. A Novel Method of Neuromonitoring in Thyroidectomy and Parathyroidectomy
Using Transcutaneous Intraoperative Vagal Stimulation. JAMA Surg 2016; 151:290.
57. Angelos P. Recurrent laryngeal nerve monitoring: state of the art, ethical and legal issues. Surg Clin North Am 2009;
89:1157.
58. Grubbs EG, Rich TA, Li G, et al. Recent advances in thyroid cancer. Curr Probl Surg 2008; 45:156.
59. Dralle H, Sekulla C, Haerting J, et al. Risk factors of paralysis and functional outcome after recurrent laryngeal nerve
monitoring in thyroid surgery. Surgery 2004; 136:1310.
60. Chan WF, Lang BH, Lo CY. The role of intraoperative neuromonitoring of recurrent laryngeal nerve during thyroidectomy: a
comparative study on 1000 nerves at risk. Surgery 2006; 140:866.
61. Cirocchi R, Arezzo A, D'Andrea V, et al. Intraoperative neuromonitoring versus visual nerve identification for prevention of
recurrent laryngeal nerve injury in adults undergoing thyroid surgery. Cochrane Database Syst Rev 2019; 1:CD012483.
62. Davey MG, Cleere EF, Lowery AJ, Kerin MJ. Intraoperative recurrent laryngeal nerve monitoring versus visualisation alone - A
systematic review and meta-analysis of randomized controlled trials. Am J Surg 2022; 224:836.
63. Pisanu A, Porceddu G, Podda M, et al. Systematic review with meta-analysis of studies comparing intraoperative
neuromonitoring of recurrent laryngeal nerves versus visualization alone during thyroidectomy. J Surg Res 2014; 188:152.
64. Vasileiadis I, Karatzas T, Charitoudis G, et al. Association of Intraoperative Neuromonitoring With Reduced Recurrent
Laryngeal Nerve Injury in Patients Undergoing Total Thyroidectomy. JAMA Otolaryngol Head Neck Surg 2016; 142:994.
65. Barczyński M, Konturek A, Cichoń S. Randomized clinical trial of visualization versus neuromonitoring of recurrent laryngeal
nerves during thyroidectomy. Br J Surg 2009; 96:240.

66. Sarı S, Erbil Y, Sümer A, et al. Evaluation of recurrent laryngeal nerve monitoring in thyroid surgery. Int J Surg 2010; 8:474.
67. Dionigi G, Boni L, Rovera F, et al. Neuromonitoring and video-assisted thyroidectomy: a prospective, randomized case-
control evaluation. Surg Endosc 2009; 23:996.
68. Al-Qurayshi Z, Randolph GW, Alshehri M, Kandil E. Analysis of Variations in the Use of Intraoperative Nerve Monitoring in
Thyroid Surgery. JAMA Otolaryngol Head Neck Surg 2016; 142:584.
69. Bergenfelz A, Salem AF, Jacobsson H, et al. Risk of recurrent laryngeal nerve palsy in patients undergoing thyroidectomy
with and without intraoperative nerve monitoring. Br J Surg 2016; 103:1828.
70. Brajcich BC, McHenry CR. The utility of intraoperative nerve monitoring during thyroid surgery. J Surg Res 2016; 204:29.
71. Thomusch O, Sekulla C, Walls G, et al. Intraoperative neuromonitoring of surgery for benign goiter. Am J Surg 2002;
183:673.
72. Osamura RY, Hunt JL. Current practices in performing frozen sections for thyroid and parathyroid pathology. Virchows Arch
2008; 453:433.
73. Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons Guidelines for Definitive
Management of Primary Hyperparathyroidism. JAMA Surg 2016; 151:959.
74. Khanna J, Mohil RS, Chintamani, et al. Is the routine drainage after surgery for thyroid necessary? A prospective
randomized clinical study [ISRCTN63623153]. BMC Surg 2005; 5:11.
75. Sanabria A, Carvalho AL, Silver CE, et al. Routine drainage after thyroid surgery--a meta-analysis. J Surg Oncol 2007; 96:273.
76. Pons Y, Gauthier J, Ukkola-Pons E, et al. Comparison of LigaSure vessel sealing system, harmonic scalpel, and conventional
hemostasis in total thyroidectomy. Otolaryngol Head Neck Surg 2009; 141:496.
77. Upadhyaya A, Hu T, Meng Z, et al. Harmonic versus LigaSure hemostasis technique in thyroid surgery: A meta-analysis.
Biomed Rep 2016; 5:221.
78. Siu JM, McCarty JC, Gadkaree S, et al. Association of Vessel-Sealant Devices vs Conventional Hemostasis With Postoperative
Neck Hematoma After Thyroid Operations. JAMA Surg 2019; 154:e193146.
79. Miccoli P, Berti P, Ambrosini CE. Perspectives and lessons learned after a decade of minimally invasive video-assisted
thyroidectomy. ORL J Otorhinolaryngol Relat Spec 2008; 70:282.

80. Miccoli P, Pinchera A, Materazzi G, et al. Surgical treatment of low- and intermediate-risk papillary thyroid cancer with
minimally invasive video-assisted thyroidectomy. J Clin Endocrinol Metab 2009; 94:1618.
81. Kang SW, Lee SC, Lee SH, et al. Robotic thyroid surgery using a gasless, transaxillary approach and the da Vinci S system:
the operative outcomes of 338 consecutive patients. Surgery 2009; 146:1048.
82. Adam MA, Speicher P, Pura J, et al. Robotic thyroidectomy for cancer in the US: patterns of use and short-term outcomes.
Ann Surg Oncol 2014; 21:3859.
83. Chai YJ, Kim HY, Kim HK, et al. Comparative analysis of 2 robotic thyroidectomy procedures: Transoral versus bilateral axillo-
breast approach. Head Neck 2018; 40:886.
84. Pan JH, Zhou H, Zhao XX, et al. Robotic thyroidectomy versus conventional open thyroidectomy for thyroid cancer: a
systematic review and meta-analysis. Surg Endosc 2017; 31:3985.
85. Lee DJ, Chin CJ, Hong CJ, et al. Outpatient versus inpatient thyroidectomy: A systematic review and meta-analysis. Head
Neck 2018; 40:192.
86. Tuggle CT, Roman S, Udelsman R, Sosa JA. Same-day thyroidectomy: a review of practice patterns and outcomes for 1,168
procedures in New York State. Ann Surg Oncol 2011; 18:1035.
87. Papoian V, Handy KG, Villano AM, et al. Randomized control trial of opioid- versus nonopioid-based analgesia after
thyroidectomy. Surgery 2020; 167:957.
88. Lancaster E, Inglis-Arkell C, Hirose K, et al. Variability in Opioid-Prescribing Patterns in Endocrine Surgery and Discordance
With Patient Use. JAMA Surg 2019; 154:1069.
89. Phitayakorn R, McHenry CR. Follow-up after surgery for benign nodular thyroid disease: evidence-based approach. World J
Surg 2008; 32:1374.
90. Haugen BR, Cooper DS, Emerson CH, et al. Expanding indications for recombinant human TSH in thyroid cancer. Thyroid
2008; 18:687.
91. Escobar-Morreale HF, Botella-Carretero JI, Escobar del Rey F, Morreale de Escobar G. REVIEW: Treatment of hypothyroidism
with combinations of levothyroxine plus liothyronine. J Clin Endocrinol Metab 2005; 90:4946.

92. Liu RH, Razavi CR, Chang HY, et al. Association of Hypocalcemia and Magnesium Disorders With Thyroidectomy in
Commercially Insured Patients. JAMA Otolaryngol Head Neck Surg 2020; 146:237.
93. Bellantone R, Lombardi CP, Raffaelli M, et al. Is routine supplementation therapy (calcium and vitamin D) useful after total
thyroidectomy? Surgery 2002; 132:1109.
94. Cayo AK, Yen TW, Misustin SM, et al. Predicting the need for calcium and calcitriol supplementation after total
thyroidectomy: results of a prospective, randomized study. Surgery 2012; 152:1059.
95. Bentrem DJ, Rademaker A, Angelos P. Evaluation of serum calcium levels in predicting hypoparathyroidism after total/near-
total thyroidectomy or parathyroidectomy. Am Surg 2001; 67:249.
96. Sywak MS, Palazzo FF, Yeh M, et al. Parathyroid hormone assay predicts hypocalcaemia after total thyroidectomy. ANZ J
Surg 2007; 77:667.
97. Noordzij JP, Lee SL, Bernet VJ, et al. Early prediction of hypocalcemia after thyroidectomy using parathyroid hormone: an
analysis of pooled individual patient data from nine observational studies. J Am Coll Surg 2007; 205:748.
98. Castro A, Del Rio L, Gavilan J. Stratifying the Risk of Developing Clinical Hypocalcemia after Thyroidectomy with Parathyroid
Hormone. Otolaryngol Head Neck Surg 2018; 158:76.
99. Mathur A, Nagarajan N, Kahan S, et al. Association of Parathyroid Hormone Level With Postthyroidectomy Hypocalcemia: A
Systematic Review. JAMA Surg 2018; 153:69.
100. Wang TS, Cheung K, Roman SA, Sosa JA. To supplement or not to supplement: a cost-utility analysis of calcium and vitamin
D repletion in patients after thyroidectomy. Ann Surg Oncol 2011; 18:1293.
101. Sanabria A, Rojas A, Arevalo J. Meta-analysis of routine calcium/vitamin D3 supplementation versus serum calcium level-
based strategy to prevent postoperative hypocalcaemia after thyroidectomy. Br J Surg 2019; 106:1126.
102. Carty SE, Doherty GM, Inabnet WB 3rd, et al. American Thyroid Association statement on the essential elements of
interdisciplinary communication of perioperative information for patients undergoing thyroid cancer surgery. Thyroid
2012; 22:395.
103. Kovatch KJ, Reyes-Gastelum D, Hughes DT, et al. Assessment of Voice Outcomes Following Surgery for Thyroid Cancer. JAMA
Otolaryngol Head Neck Surg 2019; 145:823.

104. Tuggle CT, Roman SA, Wang TS, et al. Pediatric endocrine surgery: who is operating on our children? Surgery 2008; 144:869.
105. Sosa JA, Mehta PJ, Wang TS, et al. A population-based study of outcomes from thyroidectomy in aging Americans: at what
cost? J Am Coll Surg 2008; 206:1097.
106. Boudourakis LD, Wang TS, Roman SA, et al. Evolution of the surgeon-volume, patient-outcome relationship. Ann Surg 2009;
250:159.
107. Sosa JA, Bowman HM, Tielsch JM, et al. The importance of surgeon experience for clinical and economic outcomes from
thyroidectomy. Ann Surg 1998; 228:320.
108. Stavrakis AI, Ituarte PH, Ko CY, Yeh MW. Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine
surgery. Surgery 2007; 142:887.
109. Mitchell J, Milas M, Barbosa G, et al. Avoidable reoperations for thyroid and parathyroid surgery: effect of hospital volume.
Surgery 2008; 144:899.
110. Adam MA, Thomas S, Youngwirth L, et al. Is There a Minimum Number of Thyroidectomies a Surgeon Should Perform to
Optimize Patient Outcomes? Ann Surg 2017; 265:402.
111. Taye A, Inabnet WB 3rd, Pan S, et al. Post-thyroidectomy emergency room visits and readmissions: Assessment from the
Collaborative Endocrine Surgery Quality Improvement Program (CESQIP). Am J Surg 2020; 220:813.
112. Bononi M, Amore Bonapasta S, Vari A, et al. Incidence and circumstances of cervical hematoma complicating
thyroidectomy and its relationship to postoperative vomiting. Head Neck 2010; 32:1173.
113. Harding J, Sebag F, Sierra M, et al. Thyroid surgery: postoperative hematoma--prevention and treatment. Langenbecks Arch
Surg 2006; 391:169.
114. Weiss A, Lee KC, Brumund KT, et al. Risk factors for hematoma after thyroidectomy: results from the nationwide inpatient
sample. Surgery 2014; 156:399.
115. Doran HE, Wiseman SM, Palazzo FF, et al. Post-thyroidectomy bleeding: analysis of risk factors from a national registry. Br J
Surg 2021; 108:851.
116. Campbell MJ, McCoy KL, Shen WT, et al. A multi-institutional international study of risk factors for hematoma after
thyroidectomy. Surgery 2013; 154:1283.

117. Quimby AE, Wells ST, Hearn M, et al. Is there a group of patients at greater risk for hematoma following thyroidectomy? A
systematic review and meta-analysis. Laryngoscope 2017; 127:1483.
118. Iliff HA, El-Boghdadly K, Ahmad I, et al. Management of haematoma after thyroid surgery: systematic review and
multidisciplinary consensus guidelines from the Difficult Airway Society, the British Association of Endocrine and Thyroid
Surgeons and the British Association of Otorhinolaryngology, Head and Neck Surgery. Anaesthesia 2022; 77:82.
119. Lee YS, Nam KH, Chung WY, et al. Postoperative complications of thyroid cancer in a single center experience. J Korean Med
Sci 2010; 25:541.
120. Vidal Fortuny J, Sadowski SM, Belfontali V, et al. Randomized clinical trial of intraoperative parathyroid gland angiography
with indocyanine green fluorescence predicting parathyroid function after thyroid surgery. Br J Surg 2018; 105:350.
121. Benmiloud F, Godiris-Petit G, Gras R, et al. Association of Autofluorescence-Based Detection of the Parathyroid Glands
During Total Thyroidectomy With Postoperative Hypocalcemia Risk: Results of the PARAFLUO Multicenter Randomized
Clinical Trial. JAMA Surg 2020; 155:106.
122. Audu P, Artz G, Scheid S, et al. Recurrent laryngeal nerve palsy after anterior cervical spine surgery: the impact of
endotracheal tube cuff deflation, reinflation, and pressure adjustment. Anesthesiology 2006; 105:898.
123. Chan TV, Grillone G. Vocal cord paralysis after laryngeal mask airway ventilation. Laryngoscope 2005; 115:1436.
124. Cinar SO, Seven H, Cinar U, Turgut S. Isolated bilateral paralysis of the hypoglossal and recurrent laryngeal nerves (Bilateral
Tapia's syndrome) after transoral intubation for general anesthesia. Acta Anaesthesiol Scand 2005; 49:98.
125. Norris BK, Schweinfurth JM. Arytenoid dislocation: An analysis of the contemporary literature. Laryngoscope 2011; 121:142.
126. Finck C. Laryngeal dysfunction after thyroid surgery: diagnosis, evaluation and treatment. Acta Chir Belg 2006; 106:378.
127. Teitelbaum BJ, Wenig BL. Superior laryngeal nerve injury from thyroid surgery. Head Neck 1995; 17:36.
128. Kern KA. Medicolegal analysis of errors in diagnosis and treatment of surgical endocrine disease. Surgery 1993; 114:1167.
129. Dralle H, Sekulla C, Lorenz K, et al. Intraoperative monitoring of the recurrent laryngeal nerve in thyroid surgery. World J
Surg 2008; 32:1358.
130. Laccourreye O, Papon JF, Kania R, et al. Intracordal injection of autologous fat in patients with unilateral laryngeal nerve
paralysis: long-term results from the patient's perspective. Laryngoscope 2003; 113:541.

131. Snyder SK, Angelos P, Carty SE, et al. Injection of bulking agents for laryngoplasty. Surgery 2018; 163:6.
132. Remacle M, Lawson G. Results with collagen injection into the vocal folds for medialization. Curr Opin Otolaryngol Head
Neck Surg 2007; 15:148.
133. Hartl DM, Travagli JP, Leboulleux S, et al. Clinical review: Current concepts in the management of unilateral recurrent
laryngeal nerve paralysis after thyroid surgery. J Clin Endocrinol Metab 2005; 90:3084.
134. Yumoto E, Sanuki T, Kumai Y. Immediate recurrent laryngeal nerve reconstruction and vocal outcome. Laryngoscope 2006;
116:1657.
135. Paniello RC. Laryngeal reinnervation. Otolaryngol Clin North Am 2004; 37:161.
136. Crumley RL. Repair of the recurrent laryngeal nerve. Otolaryngol Clin North Am 1990; 23:553.
137. Lombardi CP, Raffaelli M, De Crea C, et al. Long-term outcome of functional post-thyroidectomy voice and swallowing
symptoms. Surgery 2009; 146:1174.
138. Gohrbandt AE, Aschoff A, Gohrbandt B, et al. Changes of Laryngeal Mobility and Symptoms Following Thyroid Surgery: 6-
Month Follow-Up. World J Surg 2016; 40:636.
139. Cozzaglio L, Coladonato M, Doci R, et al. Horner's syndrome as a complication of thyroidectomy: report of a case. Surg
Today 2008; 38:1114.
140. Roh JL, Kim DH, Park CI. Prospective identification of chyle leakage in patients undergoing lateral neck dissection for
metastatic thyroid cancer. Ann Surg Oncol 2008; 15:424.
141. Park I, Her N, Choe JH, et al. Management of chyle leakage after thyroidectomy, cervical lymph node dissection, in patients
with thyroid cancer. Head Neck 2018; 40:7.
142. Chauhan A, Ganguly M, Saidha N, Gulia P. Tracheal necrosis with surgical emphysema following thyroidectomy. J Postgrad
Med 2009; 55:193.
Topic 2157 Version 33.0

GRAPHICS
Cervical block anesthesia

A) A superficial cervical block is administered posterior and deep to the sternocleidomastoid muscle (1). B) Local infiltration is also
performed along the anterior border of the sternocleidomastoid muscle (2), and a local field block (3) is performed.
Reproduced with permission from: Udelsman R. Unilateral neck exploration under local or regional anesthesia. In: Minimally Invasive Endocrine Surgery, Gagner M, Inabnet
W (Eds). Lippincott Williams & Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams & Wilkins.
http://www.lww.com
Graphic 82712 Version 7.0

Patient positioning for thyroid and parathyroid surgery
For thyroid and parathyroid surgery, the patient is positioned supine in the semi-Fowler or beach chair position, with the neck in extension.
A roll can be placed transversely under the scapulae to facilitate exposure of the anterior neck, and great care is taken to assure there is no
neck hyperextension.

Incision anatomy


The sternal notch and cricoid cartilage are palpated to help determine the incision site.
From: Fox AC, Gauger PG. Thyroid lobectomy. In: Operative Techniques in Surgery, Mulholland MW, Albo D, Dalman R, et al (Eds), Wolters Kluwer Health, Philadelphia 2015.
Copyright © 2015. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.

Creation of subplatysmal flaps


Adequate retraction helps creation of the subplatysmal flaps and prevents buttonholing the skin.
From: Fox AC, Gauger PG. Thyroid lobectomy. In: Operative Techniques in Surgery, Mulholland MW, Albo D, Dalman R, et al (Eds), Wolters Kluwer Health, Philadelphia 2015.
Copyright © 2015. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.

Middle thyroid vein

Exposure of the posterior thyroid. The thyroid is retracted toward the midline and the middle thyroid vein is divided. The areolar tissue
behind the thyroid can be bluntly dissected with scissors.
Reproduced with permission from: Fox AC, Gauger PG. Thyroid lobectomy. In: Operative Techniques in Surgery, Mulholland MW, Albo D, Dalman RL (Eds), Wolters Kluwer
Health, Philadelphia 2015. Copyright © 2015 Wolters Kluwer Health.

Superior pole vessels
Exposure of the superior pole. The cricothyroid space is opened up bluntly. Retraction of the superior pole in a lateral and inferior direction
helps to minimize the risk of injury to the external branch of the superior laryngeal nerve (dashed line).
(A) Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery,
Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams & Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams & Wilkins.
(B) Reproduced with permission from: Fox AC, Gauger PG. Thyroid lobectomy. In: Operative Techniques in Surgery, Mulholland MW, Albo D, Dalman RL (Eds), Wolters Kluwer

Anterior retraction thyroid
Anterior/medial retraction of thyroid, showing recurrent laryngeal nerve and parathyroid gland anatomy.
Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery,
Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams & Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams & Wilkins. www.lww.com.

Ligament of Berry
Ligament of Berry dissection with cautery after isthmus divided, before it is tied with Dandy clamp still on, providing retraction.

Dissection of recurrent laryngeal nerve lateral view
Anatomy of recurrent laryngeal nerve and parathyroid.

Dissection isthmus
Creating plane behind the isthmus, anterior to trachea. A cross-section diagram with the Kelly clamp in this plane.

Division isthmus
Transection of the thyroid. The junction between the isthmus and contralateral lobe is transected to remove the specimen.
(A) Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery,
Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams & Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams & Wilkins.
(B) Reproduced with permission from: Fox AC, Gauger PG. Thyroid lobectomy. In: Operative Techniques in Surgery, Mulholland MW, Albo D, Dalman RL (Eds), Wolters Kluwer

Thyroidectomy closure


Closing the strap muscles. The strap muscles are reapproximated with interrupted sutures.
Reproduced with permission from: Fox AC, Gauger PG. Thyroid lobectomy. In: Operative Techniques in Surgery, Mulholland MW, Albo D, Dalman RL (Eds), Wolters Kluwer

Lymphadenectomy for thyroid cancer

The extent of lymphadenectomy is based on the type of thyroid malignancy and the risk for lymph node metastasis.
By permission of Mayo Foundation for Medical Education and Research. All rights reserved. Copyright © 2010.

Lymph node levels of the neck
Level I, submental (IA) and submandibular (IB); level II, upper internal jugular nodes; level III, middle jugular nodes; level IV, low jugular
nodes; level V, posterior triangle nodes; level VI, central compartment; level VII, superior mediastinal nodes.
Adapted from: American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010)
published by Springer New York, Inc.

Locations of parathyroid glands
Most patients have four parathyroid glands: two superior and two inferior glands. The terms "superior" and "inferior" refer to a gland's
embryologic origin, rather than the gland's location in the neck. The parathyroids are usually in close association with the thyroid gland. The
superior parathyroid glands are usually 1 to 2 centimeters cranial to the junction of the recurrent laryngeal nerve with the inferior thyroid
artery and within 1 centimeter of the entry point for the recurrent laryngeal nerve into the ligament of Berry and the cricoid cartilage.
Superior parathyroid glands can be undescended or can be parapharyngeal, retropharyngeal, or retrotracheal within the middle
cervical/mediastinal compartment. Enlarged parathyroid glands can travel straight down the tracheoesophageal groove or the
retropharyngeal space into the chest. The two inferior parathyroid glands reside in the anterior mediastinal compartment, anterior to the
recurrent laryngeal nerve. They are most often found in the thyrothymic tract or just inside the thyroid capsule on the inferior portion of the
thyroid lobes.

Contributor Disclosures
Tracy S Wang, MD, MPH No relevant financial relationship(s) with ineligible companies to disclose. Melanie L Lyden, MD, MHPE No relevant
financial relationship(s) with ineligible companies to disclose. Julie Ann Sosa, MD, MA, FACS Grant/Research/Clinical Trial Support: Eli Lilly
[Medullary thyroid cancer]; Exelixis [Medullary thyroid cancer]. Consultant/Advisory Boards: AstraZeneca [Medullary thyroid cancer]; Eli Lilly
[Medullary thyroid cancer]; NovoNordisk [Medullary thyroid cancer]. All of the relevant financial relationships listed have been mitigated. Sally
E Carty, MD, FACS Other Financial Interest: Jaypee Brothers [Endocrine surgery]. All of the relevant financial relationships listed have been
mitigated. Wenliang Chen, MD, PhD No relevant financial relationship(s) with ineligible companies to disclose.
Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a
multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content
is required of all authors and must conform to UpToDate standards of evidence.
Conflict of interest policy

Thyroidectomy - UpToDate

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Thyroidectomy - UpToDate

Uploaded by

Copyright:

Available Formats

2/12/24, 6:37 PM Thyroidectomy - UpToDate

Official reprint from UpToDate®

Literature review current through: Jan 2024.

● Thyroid nodules. (See "Diagnostic approach to and treatment of thyroid nodules".)

● Hyperthyroidism. (See "Surgical management of hyperthyroidism", section on 'Role of surgery'.)

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 1/65

PREOPERATIVE EVALUATION AND PREPARATION

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 2/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 3/65

● Patients with preoperative hoarseness or voice changes

● Preoperative antithyroid medications and/or beta blockade to avoid thyroid storm.

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 4/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 5/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 6/65

Dissection of the thyroid gland

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 9/65

● Prophylactic lymphadenectomy should be performed only in the following situations:

Parathyroid autotransplantation — A normal-sized parathyroid gland of uncertain viability or an intracapsular/intrathyroidal

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 11/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 12/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 13/65

● To confirm parathyroid tissue [73].

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 14/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 15/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 16/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 17/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 18/65

● Evaluate and manage incisional healing.

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 19/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 20/65

● Inflammatory thyroid conditions (odds ratio [OR] 1.59, 95% CI 1.23-2.06)

● Partial thyroidectomy (OR 1.69, 95% CI 1.20-2.37)

● Chronic renal disease (predisposition to bleeding disorders; OR 1.8, 95% CI 1.08-3.03)

● Bleeding disorders (OR 3.38, 95% CI 1.76-6.50) [114]

● Benign pathology (OR 2.22, 95% CI 1.35-3.57)

● Antiplatelet/anticoagulation medications (OR 2.12, 95% CI 1.10-4.13)

● Use of a hemostatic agent (OR 1.97, 95% CI 1.21-3.18)

● Use of a drain (OR 2.79, 95% CI 1.68-4.65) [116]

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 21/65

Hypocalcemia/hypoparathyroidism — Hypocalcemia is one of the most common complications of thyroidectomy [119].

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 22/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 23/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 24/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 26/65

SOCIETY GUIDELINE LINKS

INFORMATION FOR PATIENTS

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 27/65

● Basics topics (see "Patient education: Seroma (The Basics)")

SUMMARY AND RECOMMENDATIONS

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 28/65

Use of UpToDate is subject to the Terms of Use.

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 29/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 30/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 31/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 32/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 33/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 34/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 35/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 36/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 37/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 38/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 39/65

https://www.uptodate.com/contents/thyroidectomy/print?search=anestesia cirugia de tiroides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 40/65

Cervical block anesthesia